Chemotherapy in osteosarcoma. The Scandinavian Sarcoma Group experience.
Saeter
G
G
Norwegian Radium Hospital, Oslo, Norway.
Wiebe
T
T
Wiklund
T
T
Monge
O
O
Wahlqvist
Y
Y
Engström
K
K
Forestier
E
E
Holmström
T
T
Stenwig
A E
AE
Willén
H
H
Brosjö
O
O
Follerås
G
G
Alvegård
T A
TA
Strander
H
H
D000293:Adolescent; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D002648:Child; D002945:Cisplatin / Q000008:administration & dosage; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D012516:Osteosarcoma / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D011182:Postoperative Care / Q000379:methods; D011300:Preoperative Care / Q000379:methods; D011379:Prognosis; D012042:Registries; D012537:Scandinavian and Nordic Countries / Q000453:epidemiology
D000964:Antimetabolites, Antineoplastic; D004317:Doxorubicin; D002945:Cisplatin; D008727:Methotrexate